
    
      This is a single-center, open-label, single-arm study to evaluate the safety and efficacy of
      ex-vivo expanded γδ T-lymphocytes in patients with relapsed or refractory acute myeloid
      leukemia. PBMCs will be separated from peripheral blood of suitable donors. After making them
      potential cancer killer γδ T Cells, they will be infused to the patients as an immunotherapy
      treatment.
    
  